Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Specific activity: approximately > 0.1 units/mg.Enzymatic activity was confirmed by measuring the amount of enzyme catalyzing the oxidation of 1 micromole NADPH per minute at 25C. Specific activity was expressed as units/mg protein.
Less than 1.0 EU/µg protein (determined by LAL method).
AKR1C3 Protein, 3-alpha-HSD type 2 Protein, 17-beta-HSD 5 Protein, 3-alpha-HSD type II, brain Protein, DD3 Protein, DDH1 Protein, DDX Protein, Dihydrodiol dehydrogenase 3 Protein, Dihydrodiol dehydrogenase X Protein, DD-3 Protein, HA1753 Protein, HAKRe Protein, HAKRB Protein, HSD17B5 Protein, KIAA0119 Protein, Kia0119 Protein, Prostaglandin F synthase Protein, PGFS Protein, Truncated aldoketo reductase a Protein, HluPGFS Protein, Indanol dehydrogenase Protein
DDX / AKR1C3 is a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ), and the oxidation of 9alpha,11beta-PGF2 to PGD2.